ArticleScientific reports2024
Emerging opportunities of using large language models for translation between drug molecules and indications.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Linguistics and human brain: a perspective of computational neuroscience.Cognitive neurodynamics · 2026Review
- A survey of transformer and LLM-based architectures, workflows, and systems in drug discovery.Journal of computer-aided molecular design · 2026Review
- Prompt-to-Pill: Multi-Agent Drug Discovery and Clinical Simulation Pipeline.Bioinformatics advances · 2026Article
- Medt5-bi: bidirectional translation between drug indications and molecular structures using a chemically-aware transformer.Journal of computer-aided molecular design · 2025Article
- Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development.Drug development research · 2025Review
- Drug and Clinical Candidate Drug Data in ChEMBL.Journal of medicinal chemistry · 2025Review
- Analyzing Patient Complaints in Web-Based Reviews of Private Hospitals in Selangor, Malaysia, Using Large Language Model-Assisted Content Analysis: Mixed Methods Study.JMIR formative research · 2025Article
- Large Language Models in Healthcare and Medical Applications: A Review.Bioengineering (Basel, Switzerland) · 2025Review
- Unveiling the power of language models in chemical research question answering.Communications chemistry · 2025Article
- GETgene-AI: a framework for prioritizing actionable cancer drug targets.Frontiers in systems biology · 2025Article
- Large language models and their applications in bioinformatics.Computational and structural biotechnology journal · 2024Review
- Transformer-based models for chemical SMILES representation: A comprehensive literature review.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A drug molecule is a substance that changes an organism's mental or physical state. Every approved drug has an indication, which refers to the therapeutic use of that drug for treating a particular medical condition. While the Large Language Model (LLM), a generative Artificial Intelligence (AI) technique, has recently demonstrated effectiveness in translating between molecules and their textual descriptions, there remains a gap in research regarding their application in facilitating the translation between drug molecules and indications (which describes the disease, condition or symptoms for which the drug is used), or vice versa. Addressing this challenge could greatly benefit the drug discovery process. The capability of generating a drug from a given indication would allow for the discovery of drugs targeting specific diseases or targets and ultimately provide patients with better treatments. In this paper, we first propose a new task, the translation between drug molecules and corresponding indications, and then test existing LLMs on this new task. Specifically, we consider nine variations of the T5 LLM and evaluate them on two public datasets obtained from ChEMBL and DrugBank. Our experiments show the early results of using LLMs for this task and provide a perspective on the state-of-the-art. We also emphasize the current limitations and discuss future work that has the potential to improve the performance on this task. The creation of molecules from indications, or vice versa, will allow for more efficient targeting of diseases and significantly reduce the cost of drug discovery, with the potential to revolutionize the field of drug discovery in the era of generative AI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.